Firefly Bio CEO Scott Hirsch (L) and Carolyn Bertozzi
Carolyn Bertozzi and Versant's new biotech breaks cover with $94M to use protein degraders in ADCs
In the bustling world of antibody-drug conjugates, few biopharmas have revealed ambitions for combining antibodies with protein degraders, rather than chemo or …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
